ストックスクリーナーアプリを入手
5.65
4.05%
0.22
アフターアワーズ：
5.63
-0.02
-0.35%
前日終値:
$5.43
開ける：
$5.54
24時間の取引高:
473.67K
Relative Volume:
0.05
時価総額：
$38.77M
収益：
$5.21M
当期純損益:
$-26.35M
株価収益率:
-0.1761
EPS:
-32.0862
ネットキャッシュフロー:
$-20.84M
1週間 パフォーマンス:
+78.23%
1か月 パフォーマンス:
+2,160%
6か月 パフォーマンス:
+730.88%
1年 パフォーマンス:
+767.90%
1日の値動き範囲:
$5.24
$6.05
1週間の範囲:
$3.13
$6.05
52週間の値動き範囲:
$0.129
$6.05
Plus Therapeutics Inc Stock (PSTV) Company Profile
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
5.65 | 37.26M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-03 | 開始されました | Lake Street | Buy |
| 2025-09-03 | アップグレード | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Plus Therapeutics Inc (PSTV) 最新ニュース
Plus Therapeutics appoints Randy Goodman to lead market access By Investing.com - Investing.com Australia
Plus Therapeutics Hires Randy Goodman to Lead Market Access and Value Strategy - citybiz
Plus Therapeutics appoints Randy Goodman to lead market access - Investing.com
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution - The Manila Times
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV stock on track for best week since September — here’s what is driving the rally - MSN
Why is Plus Therapeutics stock gaining Friday? - MSN
PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally - Stocktwits
Trend Report: What are the analyst revisions for Plus Therapeutics IncIs VRSN stock a good investment in YEARMarket Sentiment Review & Community Verified Watchlist Alerts - baoquankhu1.vn
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Why Is Plus Therapeutics Stock Gaining Friday?Plus Therapeutics (NASDAQ:PSTV) - Benzinga
Plus Therapeutics recives Nasdaq delinquency notice - MSN
PSTV Should I Buy - Intellectia AI
Plus Therapeutics names Eric Daniels as chief development officer By Investing.com - Investing.com Australia
Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026 - marketscreener.com
Plus Therapeutics, Inc. Files 8-K Disclosing Executive Employment Agreement and Company Information - Minichart
PSTV: Ascendiant Capital Lowers Price Target to $65 on Plus Ther - GuruFocus
Plus Therapeutics appoints Eric J. Daniels as chief development officer By Investing.com - Investing.com India
Plus Therapeutics Appoints New Chief Development Officer - TipRanks
Plus Therapeutics appoints Eric J. Daniels as chief development officer - Investing.com UK
Plus Therapeutics names Eric J. Daniels as Chief Development Officer - TradingView — Track All Markets
Plus Therapeutics (PSTV) hires Eric J. Daniels as Chief Development Officer with equity package - Stock Titan
Plus Therapeutics names Eric Daniels as chief development officer - Investing.com
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline - Bitget
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas - Sahm
Pretax income of Plus Therapeutics, Inc. – MUN:XMP1 - TradingView
Dilution adjustment of Plus Therapeutics, Inc. – MUN:XMP1 - TradingView — Track All Markets
Plus Therapeutics stock gains after FDA orphan drug nod - Investing.com
Plus Therapeutics stock gains after FDA orphan drug nod By Investing.com - Investing.com Australia
FDA grants orphan drug status to Plus Therapeutics’ REYOBIQ By Investing.com - Investing.com Australia
Plus Therapeutics (PSTV) Secures FDA Orphan Drug Designation for Reyobiq - GuruFocus
Plus Therapeutics Receives FDA Orphan Drug Designation for REYOBIQ™ in Pediatric Malignant Gliomas and Ependymoma - Minichart
Plus Therapeutics Gains FDA Orphan Status for REYOBIQ - TipRanks
Plus Therapeutics | 8-K: Current report - Moomoo
Plus Therapeutics granted Orphan Drug Designation for Reyobiq - TipRanks
FDA grants orphan drug status to Plus Therapeutics’ REYOBIQ - Investing.com
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ in Pediatric Malignant Gliomas - Bitget
FDA grants Orphan Drug Designation to REYOBIQ from Plus Therapeutics (PSTV) - Stock Titan
FDA orphan status backs Plus drug for rare childhood brain tumors - Stock Titan
Total debt of Plus Therapeutics, Inc. – FWB:XMP1 - TradingView
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption - Sahm
Average basic shares outstanding of Plus Therapeutics, Inc. – FWB:XMP1 - tradingview.com
Equity in earnings of Plus Therapeutics, Inc. – FWB:XMP1 - TradingView — Track All Markets
Gross margin % of Plus Therapeutics, Inc. – FWB:XMP1 - TradingView
EBITDA per share of Plus Therapeutics, Inc. – GETTEX:XMP1 - TradingView — Track All Markets
Plus Therapeutics Inc (PSTV) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):